ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting

18 مارس 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting

09 مارس 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 مارس 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

28 فبراير 2023 16:02:00 بحسب Nasdaq GlobeNewswire

Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents

21 فبراير 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference

08 فبراير 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 فبراير 2023 16:09:57 بحسب Nasdaq GlobeNewswire

Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis

14 يناير 2023 04:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 يناير 2023 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age

19 ديسمبر 2022 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older

12 ديسمبر 2022 08:00:53 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 ديسمبر 2022 16:01:00 بحسب Nasdaq GlobeNewswire

Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255

05 ديسمبر 2022 08:00:00 بحسب Nasdaq GlobeNewswire

Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology

28 نوفمبر 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report

21 نوفمبر 2022 09:15:00 بحسب Nasdaq GlobeNewswire

CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

15 نوفمبر 2022 11:09:55 بحسب Nasdaq GlobeNewswire

Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

15 نوفمبر 2022 08:00:02 بحسب Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

11 نوفمبر 2022 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update

08 نوفمبر 2022 16:02:00 بحسب Nasdaq GlobeNewswire

Arcutis to Report Third Quarter Financial Results

25 أكتوبر 2022 16:05:00 بحسب Nasdaq GlobeNewswire